2016 International Congress

Thursday, June 23, 2016

12:00pm-1:30pm

Therapy escalation in Parkinson’s disease – The TEMP trial, a regional survey

F. Gandor, A. Kühn, J. Müller, F. Klostermann, T. Müller, D. Gruber, A. Lipp, A. Kivi, D. Kübler, F. Ehlen, G. Ebersbach (Beelitz-Heilstätten, Germany)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

TNF compromises lysosome acidification and reduces α-synuclein degradation via autophagy in dopaminergic cells

X. Cheng, M. Wang (Suzhou, People's Republic of China)

Other  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Tourette syndrome and attention deficit hyperactivity disorders

K. Aminov (Tashkent, Uzbekistan)

Pediatric movement disorder  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Transcranial versus root repeated magnetic stimulation as a treatment of psychogenic movement disorders

B. Garcin, C. Hubsch, L. Lliescu, L. Naccache, M. Vidailhet, E. Fournier, F. Mesrati, E. Roze, B. Degos (Paris, France)

Parkinson's Disease: Clinical Trials II and Non-PD Clinical Trials

12:00pm-1:30pm

Triad-conditioning transcranial magnetic stimulation in focal hand dystonia

T. Popa, R. Hunt, O. Ahmad, K. Mente, R. Paine, M. Hallett (Bethesda, MD, USA)

Dystonia  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Unilateral pallidotomy for cervical dystonia

S. Horisawa, T. Ishikawa, T. Hanada, T. Kawamata, T. Taira (Shinjuku, Japan)

Dystonia  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Upper limb motor tests are related to clinical ratings of motor function in advanced Parkinson’s disease

M. Memedi, S. Aghanavesi, D. Nyholm, H. Askmark, S.M. Aquilonius, R. Constantinescu, F. Bergquist, A. Medvedev, A. Ericsson, F. Ohlsson, S. Lycke, J. Spira, M. Senek, J. Westin (Falun, Sweden)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Use of nicotine gum to treat acute low blood pressure in Parkinson’s disease

J. DiFrancisco-Donoghue, A. Leder, M.K. Jung, W.G. Werner (Old Westbury, NY, USA)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Utility of IgGs subtypes in hemolytic anemia prevention and treatment maintenance in patients treated with continous infusion of apomorphine

P. Sanchez-Lozano, E. Suarez, R. Ribacoba (Gijon, Spain)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Utilization and longitudinal impact of amantadine use in Parkinson’s disease. National Parkinson Foundation (NPF) QII registry

V. Felix Saunders, T. Simuni, K. Li, S. Luo (Chicago, IL, USA)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2